Paper II — 2025 March (Supplementary (SAY)) (2019 Scheme) — Qxx
2 min read
Paper II
2025 March (Supplementary (SAY)) (2019 Scheme) · 100 marks · 180 min
Question
All are true statement about HER2 positive invasive carcinoma breast EXCEPT
a) More common in young women
b) Metastasize early to viscera and brain
c) Targeted therapy available
d) Most common carcinoma associated with BRCA 2 germline mutation
(PTO)
Qxx1 marksMCQs
Answer
Correct answer: d) Most common carcinoma associated with BRCA 2 germline mutation
(PTO)
This is the exception (FALSE statement). BRCA2-associated breast carcinomas are typically hormone receptor-positive (ER/PR+) and HER2-negative (a luminal-like phenotype), not HER2-positive; BRCA1-associated cancers, in turn, are more typically triple-negative/basal-like. The other statements about HER2-positive breast carcinoma are genuinely true: it tends to occur more often in younger women (option a), shows a propensity for early visceral and brain metastasis (option b), and has effective targeted therapy available (anti-HER2 agents such as trastuzumab and pertuzumab, option c).
Checkpoint: This completes all 8 sittings of Pathology qpCode 214001 (Paper II, new/CBME scheme) — 176/176 questions answered, 0 stubs remaining. One additional gap for the developer team: printedNumber “1” (the first Long Essay) of this 2025-March (Supplementary (SAY)) sitting has no corresponding scaffold file at all in the source data — this appears to be a missing-ingestion gap (the paper’s numbering jumps from a section header directly to printedNumber “2”), distinct from the leaked-content gaps found elsewhere; flagged here for the ingestion team, no new scaffold file created.
